In just a short span of time, Ozempic, also popularly known as the ‘miracle’ weight loss drug, has become the talk of the ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the ...

A study of real-world and virtual patients suggests that a less frequent dosing of glucagon-like peptide 1 receptor agonists ...

Dementia experts have said that “hope is on the horizon” after a new review shows a rise in the number of potential drugs that could treat or prevent Alzheimer’s disease. Some 138 treatments are being ...

Mazdutide, used in the treatment of obesity and metabolic diseases, could become the first domestically-developed dual-target ...

Are you tired of boring dieting and gruesome workouts? Then, medical weight loss treatment can be a solution for you. But ...

A study from the University of Gothenburg identifies specific brain neurons controlling semaglutide's weight loss effects.

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

Wegovy and other GLP-1 obesity and blood sugar control drugs accounted for 17% of pharmacy benefits spending at CBIZ employer ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...